<DOC>
	<DOCNO>NCT00913432</DOCNO>
	<brief_summary>A 12-week possible extension , phase II study compare efficacy safety masitinib 3 6 mg/kg/day combination methotrexate , treatment patient active rheumatoid arthritis refractory standard treatment .</brief_summary>
	<brief_title>A Phase 2 Study Evaluate Efficacy Safety Masitinib Combination With Methotrexate , Treatment Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>1 . Disease duration least 6 month Meet American College Rheumatology ( ACR ) criterion RA . 2 . ACR functional class IIII 3 . Have active RA 4 . Failed ( define active RA stable dose 3 month ) i. methotrexate ii . DMARD include anti TNF alpha patient previously fail methotrexate iii . methotrexate combination DMARD include anti TNF alpha 1 . Patient major surgery within 2 week prior study entry . 2 . Life expectancy &lt; 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>methotrexate</keyword>
	<keyword>DMARD</keyword>
	<keyword>c-kit inhibitor</keyword>
</DOC>